biOasis welcomes Doug Williams, as Executive VP and Chief Business Officer, effective immediately.
Williams will report to Dr Mark Day, President and CEO of biOasis. In this newly created position, Williams will provide leadership and execute on the corporate development strategy, to maximise benefits for strategic partners and shareholders.
Williams will be responsible for leading corporate and business development, and the alliance management efforts at biOasis.
Dr Day said: “We are delighted to welcome Doug Williams to our senior management team at biOasis.
"I know he will bring value as a business development leader and well-respected and strategic alliance professional.
"Doug will play a critical role in advancing our partnering strategy and create value through the prosecution of licensing opportunities for our proprietary blood-brain barrier drug delivery platform."
Williams has more than 20 years of experience in the pharmaceutical and healthcare industries and has successfully led cross-functional, global alliances teams across multiple organisations.
His alliance and partnering experience includes a broad set of partners including large, multinational pharmaceutical companies and start-up biotechnology companies, including global alliances with Shionogi, Exicure, AbbVie, Mylan and Takeda.
Williams has been recognised as an industry leader who has presented, participated as a panelist and moderated multiple industry partnering programmes at industry events.
Rob Hutchison, Founder and Chairman of the Board of Directors at biOasis, said: "Doug has a broad set of experiences having worked in leadership roles at healthcare technology start-ups, pharmaceutical and biotechnology companies. His diverse experience base will help propel our global partnering efforts. Doug will be a great addition to the biOasis leadership team."
Williams most recently came from Purdue Pharma L.P where he worked on strategic alliances and business development projects related to clinical and pre-clinical programmes. Prior to Purdue, Williams built his own successful consulting business working with start-up healthcare technology companies.
His experience includes commercial sales, sales management, alliance management and business development. He has also held various positions of increasing responsibility at Pfizer, Johnson & Johnson, Elan, Sepracor and Kadmon during his 20 year career.
Williams said: “I am eager to work with Mark on shaping the business strategy for biOasis as we continue to advance our proprietary blood-brain barrier technology platform. I want to thank Rob and Mark for this opportunity. I look forward to sharing the biOasis story with new potential collaborators and leading the licensing and partnering efforts on behalf of the company and our shareholders."
